Pfizer lashes out at ‘frustrating’ NICE decision on ALL drug Besponsa
admin 21st August 2017 Uncategorised 0Pfizer’s new targeted drug for the treatment of acute lymphoblastic leukemia (ALL) last week won FDA approval after already getting a nod by the EU. But U.K. cost watchdog NICE today snubbed Besponsa, eliciting a quick and heated response from the U.S. drugmaker.
More: Pfizer lashes out at ‘frustrating’ NICE decision on ALL drug Besponsa
Source: fierce